UK Diagnostic Fret Over Loss of Support In Evidence Centers Restructure
Executive Summary
Changes are afoot for the four UK Diagnostic Evidence Co-operatives that help generate clinical and cost-effectiveness data for innovative IVDs. Companies worry it could mean diagnostic industry needs get lost among broad medtech targets. Also, a roundup of the British In Vitro Diagnostics Association's key priorities, including the EU IVD Regulation, procurement issues, antimicrobial resistance, and of course, Brexit, highlighted at the group's 2016 annual meeting.
You may also be interested in...
Diagnostics Marks 'NHS 70' With New UK Push On AMR
The National Health Service (NHS) came into being in the UK 70 years ago today, and to mark the occasion, NHS England and UK diagnostics stakeholders have officially launched a new prevention initiative: the UK AMR Diagnostic Collaborative. Its targeted actions and recommendations will help the NHS – and global systems – tackle the ever-larger-looming issue of antimicrobial resistance.
UK Medtech Market Access In Practice: Aim High But Stay Grounded
Manufacturers must ensure there are commercial outlets for the products they are developing, given the speed of change in medtech markets. That was the key message for companies and innovators at the UK Med-Tech Expo Conference 2017.
Amid Reforms, Brexit, UK IVD Firms Battle Funding And Adoption Issues
The EU In Vitro Diagnostics Regulation and Brexit loom large for UK IVD companies, but manufacturers serving the $1.6bn UK IVD market have many other competing concerns. It’s the most challenging period in more than 15 years, according to the British In Vitro Diagnostics Association Chief Executive Doris-Ann Williams.